Clinical trials: Anti-inflammatory Agents
Rheumatoid Arthritis
Three Dose Levels of CP-690,550 Monotherapy Versus Placebo, Administered Orally Twice Daily (BID) for 6 Weeks
The study's objective is to compare the efficacy of 3 dose levels of oral CP-690,550 monotherapy (5 mg, 15 mg, and 30 mg twice daily [BID]) versus placebo administered over 6 weeks for the treatment of the signs and symptoms of…
- Trial name
- NCT00147498
- Testing
- CP-690,550
- Where
- 60 sites in United States, Belgium and 7 more
- Volunteers
- 264 people
- Sponsor
- Pfizer
Ankylosing Spondylitis
Post-authorization Safety Study of Etoricoxib and Other Anti-inflammatory Therapies in European Patients With Ankylosing Spondylitis (MK-0663-163)
This study is a population-based cohort of patients with ankylosing spondylitis (AS) from general medical practices in the UK, France, and Germany with a nested case control component to assess associations between drug exposures…
- Trial name
- NCT01077843
- Testing
- Etoricoxib, Other Cox-2 inhibitors, Other Non-selective NSAIDs
- Volunteers
- 27,381 people
- Sponsor
- Organon and Co
Eosinophilic Esophagitis
Efficacy and Safety APT-1011 in Adolescent Subjects With Eosinophilic Esophagitis (EoE) - A Sub-Study of the FLUTE-2 Trial
This is a randomized, double-blind, placebo-controlled study of APT-1011, followed by an open-label extension (OLE) in adolescents (≥12 to <18 years) with EoE.
- Trial name
- FLUTEEN (NCT05083312)
- Testing
- APT-1011
- Where
- 3 sites in United States, Australia
- Volunteers
- 6 people
- Sponsor
- Ellodi Pharmaceuticals, LP
Low Back Pain, Mechanical, Low Back Pain
Efficacy and Safety of S (+) - Ibuprofen in the Treatment of Mechanical Low Back Pain
The purpose of this study is to evaluate the efficacy of S (+) - ibuprofen compared to an active treatment for pain control in individuals with at least moderate acute mechanical low back pain.
- Conditions
- Low Back Pain, Mechanical, Low Back Pain, Acute Low Back Pain
- Trial name
- APS002/2020 (NCT04772781)
- Testing
- S (+) - Ibuprofen, Ibuflex®
- Where
- Brazil
- Volunteers
- 177 people
- Sponsor
- Apsen Farmaceutica S.A.
Cutaneous Inflammation
Study on Anti-inflammatory Effects of Topical R115866 Gel
The purpose of this exploratory trial is to assess the anti-inflammatory effect(s) of topical R115866 in a model of UVB-induced inflammation and in a model of cutaneous irritation.
- Trial name
- NCT00719121
- Testing
- Talarozole, Differin™, 0.1% adapalene gel
- Where
- Belgium
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Stiefel, a GSK Company
Chronic Obstructive Pulmonary Disease
Unrefined Salmon Oil as Dietary Supplement in Patient With Chronic Obstructive Pulmonary Disease
Research has over decades showed that marine food carries nutritional characteristics that promote human health. As seen in epidemiological studies and based on in vitro and in vivo studies, it is hypothesized that unrefined…
- Trial name
- NCT05130294
- Testing
- CARDIO®
- Where
- Norway
- Sponsor
- Hofseth Biocare ASA
Arthritis, Rheumatoid
Safety and Tolerability Study of MBS2320 in Healthy Subjects and Subjects With Rheumatoid Arthritis
Rheumatoid arthritis (RA) affects 1 percent of the population worldwide and up to 40 percent of patients don't respond to current treatments.
- Trial name
- NCT02480946
- Testing
- MBS2320, Methotrexate
- Where
- 3 sites in United Kingdom
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Modern Biosciences Ltd
Arthritis, Rheumatoid
Comparing The Effectiveness And Safety Of 2 Doses Of An Experimental Drug, CP-690,550, To Methotrexate (MTX) In Patients With Rheumatoid Arthritis Who Have Not Previously Received MTX
This study is designed to compare the effectiveness of the experimental drug, CP-690,550, to methotrexate in preventing joint damage and improving symptoms of rheumatoid arthritis.
- Trial name
- ORAL1069 (NCT01039688)
- Testing
- CP-690,550, Disease-modifying antirheumatic drug
- Where
- 176 sites in United States, Argentina and 28 more
- Volunteers
- 956 people
- Sponsor
- Pfizer
Ulcerative Colitis
The Efficacy of Cobitolimod in Patients With Moderate to Severe Active Ulcerative Colitis
The purpose of this study was to evaluate efficacy of cobitolimod treatment at different dose levels and frequencies compared to placebo in patients with moderate to severe left-sided ulcerative colitis.
- Trial name
- CONDUCT (NCT03178669)
- Testing
- cobitolimod
- Where
- 64 sites in Czechia, France and 8 more
- Volunteers
- 213 people
- Sponsor
- InDex Pharmaceuticals
Cystic Fibrosis
SD Cystic Fibrosis Study
Subject with Cystic Fibrosis have increased clearance of many drugs. Based on pre-clinical data SB656933 was found to have low clearance and high bio-availability.
- Trial name
- NCT00605761
- Testing
- SB656933
- Where
- 3 sites in United States
- Volunteers
- 9 people
- Sponsor
- GlaxoSmithKline
Arthritis, Rheumatoid
The Anti-Inflammatory And Metabolic Effects Of Rosiglitazone In Subjects With Rheumatoid Arthritis
To assess whether the anti-inflammatory effects of rosiglitazone result in improvements in Rheumatoid Arthritis symptoms in patients for whom their existing Disease Modifying Anti-Rheumatic Drug (DMARD) treatment does not give…
- Trial name
- NCT00379600
- Testing
- rosiglitazone XR
- Where
- 5 sites in Lithuania, United Kingdom
- Volunteers
- 96 people
- Sponsor
- GlaxoSmithKline
Psoriasis
BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
This is a randomized double blind, double dummy, active comparator controlled, parallel design study that is performed to assess the safety and efficacy of BI 655066/ABBV-066 (risankizumab) compared to adalimumab to support…
- Trial name
- NCT02694523
- Testing
- risankizumab, adalimumab
- Volunteers
- 684 people
- Sponsor
- AbbVie
Rheumatoid Arthritis
Safety, Tolerance, Pharmacokinetics and Activity of HE3286 in Patients With Rheumatoid Arthritis
The purpose of this pilot, exploratory study is to evaluate the safety, tolerance, pharmacokinetics and potential anti-inflammatory activity of an investigational agent, HE3286, when administered orally for 29 days to patients…
- Trial name
- NCT00712114
- Testing
- HE3286
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Harbor Therapeutics
Inflammation
Efficacy and Safety of Bovine Intestinal Alkaline Phosphatase (bIAP) During Heart Surgery
This multi-centre prospective, randomised, double-blind, placebo-controlled study is designed to evaluate the efficacy and safety of bovine intestinal alkaline phosphatase (bIAP) in reducing the pro-inflammatory post-surgical…
- Trial name
- APPIRED-II (NCT01144611)
- Testing
- bIAP bolus and 8h infusion
- Where
- Netherlands
- Volunteers
- 53 people
- Sponsor
- Alloksys Life Sciences B.V.
Osteoarthritis
A Prospective Observational Study on Discontinuation of Medication of Shinbaro Capsule
This study investigates how gastrointestinal toxicity affects discontinuation of medication given to patients with osteoarthritis in routine clinical practice.
- Trial name
- NCT02064634
- Where
- South Korea
- Volunteers
- 6,700 people
- Sponsor
- Green Cross Corporation
Knee Osteoarthritis
Clinical Study of Artz in the Treatment of Knee Osteoarthritis
This is a multi-center, randomized, open-label, parallel-arm phase IV clinical study, for which a total of 300 patients with mild to moderate knee osteoarthritis will be enrolled.
- Trial name
- Artz (NCT02826031)
- Testing
- Sodium Hyaluronate Injection, DICL-SR
- Where
- 6 sites in China
- Volunteers
- 300 people
- Sponsor
- Kunming Baker Norton Pharmaceutical Sales Co., Ltd.
Ulcerative Colitis
The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis
The purpose of the study is to evaluate the efficacy of cobitolimod treatment compared to placebo in inducing clinical remission, in participants with moderate to severe active left-sided UC and to evaluate the efficacy of…
- Trial name
- CONCLUDE (NCT04985968)
- Testing
- Cobitolimod 250 mg, Cobitolimod 500 mg
- Where
- 203 sites in United States, Australia and 26 more
- Volunteers
- 171 people
- Sponsor
- InDex Pharmaceuticals
Acute Gout
Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicine Including a 12 Weeks Extension and an Open-label 48 Weeks Extension Study
The purpose of the 12-week core study was to demonstrate that canakinumab given upon acute gout flares relieves the signs and symptoms and prevents recurrence of gout flares in patients with frequent flares of gout for whom…
- Trial name
- β-RELIEVED (NCT01029652)
- Testing
- Canakinumab 150 mg, Triamcinolone acetonide 40 mg
- Where
- 47 sites in Australia, Belgium and 15 more
- Volunteers
- 230 people
- Sponsor
- Novartis Pharmaceuticals
Postoperative Bariatric Surgery
Use Of Esomeprazole In Postoperative Bariatric Surgery Patients Users And Non-Users Of Nonsteroidal Anti-Inflammatory Drugs (NSAIDS)
Phase IV, open-label, multicenter, non-randomized, with 2 non-comparative investigational arms study, carried out in morbid obesity patients who had undergone gastric bypass surgery for body weight reduction
- Trial name
- NCT00608712
- Testing
- Esomeprazole
- Volunteers
- 140 people
- Sponsor
- AstraZeneca
Dry Eye Disease (DED)
A Non-interventional Study to Evaluate the Anti-inflammatory Effects and the Clinical Efficacy of Topical Water Free Cyclosporin 0.1% Eye Drops in Patients With Dry Eye Disease and Associated Ocular Surface Inflammation Non-responding to Artificial Tears: the FOCUS Study
The FOCUS study aims to evaluate the clinical efficacy of 0.1% cyclosporine eye drops solution (Vevizye®, Laboratoires THEA) in patients with moderate to severe dry eye disease characterized by ocular surface inflammation.
- Trial name
- NCT07234318
- Testing
- Cyclosporin
- Where
- Austria
- Volunteers
- 25 people
- Sponsor
- Laboratoires Thea